Detalhe da pesquisa
1.
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(12): 1423-1433, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37944541
2.
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Blood
; 138(21): 2031-2041, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407542
3.
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Lancet Oncol
; 17(3): 319-331, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26899778
4.
Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience.
Front Oncol
; 13: 1138683, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37007128
5.
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Leukemia
; 37(3): 617-626, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36717654
6.
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
J Clin Oncol
; 41(21): 3689-3699, 2023 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37279408
7.
Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.
NEJM Evid
; 1(7): EVIDoa2200006, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38319255